259 related articles for article (PubMed ID: 23066150)
1. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
[TBL] [Abstract][Full Text] [Related]
2. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
Kellner C; Günther A; Humpe A; Repp R; Klausz K; Derer S; Valerius T; Ritgen M; Brüggemann M; van de Winkel JG; Parren PW; Kneba M; Gramatzki M; Peipp M
Oncoimmunology; 2016; 5(1):e1058459. PubMed ID: 26942070
[TBL] [Abstract][Full Text] [Related]
3. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
[TBL] [Abstract][Full Text] [Related]
4. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
5. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
[TBL] [Abstract][Full Text] [Related]
6. Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.
Xu X; Narni-Mancinelli E; Cantoni C; Li Y; Guia S; Gauthier L; Chen Q; Moretta A; Vély F; Eisenstein E; Rangarajan S; Vivier E; Mariuzza RA
J Mol Biol; 2016 Nov; 428(22):4457-4466. PubMed ID: 27663271
[TBL] [Abstract][Full Text] [Related]
7. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
[TBL] [Abstract][Full Text] [Related]
8. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
9. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
[TBL] [Abstract][Full Text] [Related]
10. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
Schlecker E; Fiegler N; Arnold A; Altevogt P; Rose-John S; Moldenhauer G; Sucker A; Paschen A; von Strandmann EP; Textor S; Cerwenka A
Cancer Res; 2014 Jul; 74(13):3429-40. PubMed ID: 24780758
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
Semeraro M; Rusakiewicz S; Minard-Colin V; Delahaye NF; Enot D; Vély F; Marabelle A; Papoular B; Piperoglou C; Ponzoni M; Perri P; Tchirkov A; Matta J; Lapierre V; Shekarian T; Valsesia-Wittmann S; Commo F; Prada N; Poirier-Colame V; Bressac B; Cotteret S; Brugieres L; Farace F; Chaput N; Kroemer G; Valteau-Couanet D; Zitvogel L
Sci Transl Med; 2015 Apr; 7(283):283ra55. PubMed ID: 25877893
[TBL] [Abstract][Full Text] [Related]
13. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
[TBL] [Abstract][Full Text] [Related]
15. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.
Brandt CS; Baratin M; Yi EC; Kennedy J; Gao Z; Fox B; Haldeman B; Ostrander CD; Kaifu T; Chabannon C; Moretta A; West R; Xu W; Vivier E; Levin SD
J Exp Med; 2009 Jul; 206(7):1495-503. PubMed ID: 19528259
[TBL] [Abstract][Full Text] [Related]
16. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.
Zou Y; Bao J; Pan X; Lu Y; Liao S; Wang X; Wang G; Lin D
PLoS One; 2015; 10(8):e0134568. PubMed ID: 26241657
[TBL] [Abstract][Full Text] [Related]
17. Important role for NKp30 in synapse formation and activation of NK cells.
Wang H; Zheng X; Wei H; Tian Z; Sun R
Immunol Invest; 2012; 41(4):367-81. PubMed ID: 22221078
[TBL] [Abstract][Full Text] [Related]
18. At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity.
Danielou-Lazareth A; Henry G; Geromin D; Khaznadar Z; Briere J; Tamouza R; Cayuela JM; Thieblemont C; Toubert A; Dulphy N
Eur J Immunol; 2013 May; 43(5):1383-8. PubMed ID: 23400905
[TBL] [Abstract][Full Text] [Related]
19. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
Zhang T; Wu MR; Sentman CL
J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709
[TBL] [Abstract][Full Text] [Related]
20. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.
Li Y; Wang Q; Mariuzza RA
J Exp Med; 2011 Apr; 208(4):703-14. PubMed ID: 21422170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
